Cardiovascular Disease Progression in Survivors of Community Acquired Pneumonia and Lung Infection by Covid-19.
A legfontosabb adatok
- Ki végzi
- Hellenic Institute for the Study of Sepsis
- Hol
- Görögország19 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Toboroz
- Résztvevők
- 650 fő, tervezett
- Kezdés
- 2024. nov. 8.
- Várható befejezés
- 2028. jún. 8.
- A vizsgálat típusa
- Megfigyeléses, 4 csoport
- A vizsgált kezelések
- Blood samples and Oropharyngeal swab
- Six-minute walk test, Spirometry, ECG, Heart ultrasound and cardiopulmonary exercise stress testing, Completion of questionnaires of symptoms
- A regiszteradat frissítve
- 2026. november 6.
Ki vehet részt
- Életkor
- 18 év felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Részt vehetnek
A regiszter feltételei, szó szerint
Mind a 29 feltétel megnézéseKevesebb
Ki vehet részt
- Group A (healthy controls)
- Adults (18 years or more) of both genders (Female/Male: 50/50 ratio)
- No history of severe pneumonia (sCAP, COVID-19 or HAP)
- Presence of no or one of the following comorbidities: obesity (defined as body mass index over 35 kg/m2), type 2 diabetes mellitus, hypercholesterolemia, essential arterial hypertension, or familial history of CVD; Group B (CVRD controls)
- Adults (18 years or more) of both genders (Female/Male ratio: 50/50)
- No history of severe pneumonia (sCAP, COVID-19 or HAP)
- At least two of the following comorbidities: obesity (defined as body mass index over 35 kg/m2), type 2 diabetes mellitus, hypercholesterolemia, essential arterial hypertension, or familial history of CVD; Group C (COVID-19 survivors)
- Adults (18 years or more) of both genders (Female/Male ratio: 50/50)
- Survivors from severe COVID-19 pneumonia at hospital discharge; all patients had consolidation in chest X-ray or chest computed tomography during acute infection and were treated for pneumonia
- SoC treatment for acute COVID-19 with dexamethasone; Group D (sCAP survivors)
- Adults (18 years or more) of both genders
- Survivors from sCAP pneumonia; these patients may be either hospitalized in the ward with pO2FiO2 ratio less than 300 or require admission and hospitalization in the Intensive Care Unit
- SoC treatment for sCAP with antibiotics
Ki nem vehet részt
- Any other co-existing disorder generating CVRD symptoms
- Any other co-existing disorder generating CVRD symptoms
- Pregnancy or lactation; Group C (COVID-19 survivors)
- Medical history of severe congestive heart failure (Stage III-IV)
- Medical history of stage III or IV dyspnoea according to the New York Heart Association classification before the acute COVID-19
- Medical history of severe congestive heart failure (Stage III-IV)
- Medical history of stage III or IV dyspnoea according to the New York Heart Association classification before the sCAP
- Group A (healthy controls)
- Presence of two or more comorbidities
- Limited chance of survival for at least six months due to co-existing comorbidity (-ies) according to the judgement of the attending physicians
- Pregnancy or lactation; Group B (CVRD controls)
- Limited chance of survival for at least six months due to co-existing comorbidity (-ies) according to the judgement of the attending physicians
- Limited chance of survival for at least six months due to co-existing comorbidity (-ies) according to the judgement of the attending physicians
- Pregnancy or lactation; Group D (sCAP survivors)
- Limited chance of survival for at least six months due to co-existing comorbidity (-ies) according to the judgement of the attending physicians
- Pregnancy or lactation
Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
Pneumonia, which can be acquired in the community (including influenza and COVID-19), is a leading cause of mortality. The risk of severe cardiovascular diseases events (stroke, myocardial infarction, pulmonary embolism) increases after infections, but causal mechanisms are not understood yet. There is an essential need for improved understanding of the relationship between pneumonia and cardiovascular diseases and early identification of patients at risk of cardiovascular events to develop tailored therapies.
A teljes eredeti leírásKevesebb
The overall concept underpinning "Homi-lung" is to investigate the time course of host-microbiome interactions during \& after pneumonia to i) understand the causal relationship between trained immunity, microbiome dysbiosis and cardiovascular and respiratory diseases (CVRD) progressions, ii) define endotypes of pneumonia associated with response to treatment \& CVRD history; iii) develop biomarkers to predict the individual response to the treatment \& CVRD progression, and iv) preclinically validate therapeutical approaches for CVRD during \& after pneumonia.
A vizsgálat 4 csoportja
- Healthy controls
Controls with no or one comorbidity, predisposing to significant CV events and without a medical history of severe pneumonia.
Kezelés: Blood samples and Oropharyngeal swab
- CVRD controls
Controls with comorbidities predisposing to major CV events and without a medical history of severe pneumonia
Kezelés: Blood samples and Oropharyngeal swab és Six-minute walk test, Spirometry, ECG, Heart ultrasound and cardiopulmonary exercise stress testing, Completion of questionnaires of symptoms
- COVID-19 survivors
Patients cured of acute COVID-19
Kezelés: Blood samples and Oropharyngeal swab és Six-minute walk test, Spirometry, ECG, Heart ultrasound and cardiopulmonary exercise stress testing, Completion of questionnaires of symptoms
- sCAP survivors
Patients cured of severe community-acquired pneumonia
Kezelés: Blood samples and Oropharyngeal swab és Six-minute walk test, Spirometry, ECG, Heart ultrasound and cardiopulmonary exercise stress testing, Completion of questionnaires of symptoms
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Non-interventional, Prospective, Cross-sectional Study of Cardiovascular Disease Progression in Survivors of Community Acquired Pneumonia and Lung Infection by Sars-Cov-2
- A regiszteradat frissítve
- 2026. november 6.